Search Results - "van Echo, D."

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients by Mittendorf, E.A., Clifton, G.T., Holmes, J.P., Schneble, E., van Echo, D., Ponniah, S., Peoples, G.E.

“…E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II…”
Get full text

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors by CONLEY, B. A, EGORIN, M. J, TAIT, N, ROSEN, D. M, SAUSVILLE, E. A, DOVER, G, FRAM, R. J, VAN ECHO, D. A

“…Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate…”
Get full text

Pleurx tunneled catheter in the management of malignant ascites by Richard, 3rd, H M, Coldwell, D M, Boyd-Kranis, R L, Murthy, R, Van Echo, D A

“…The authors report their experience with the Pleurx tunneled catheter in patients with end-stage abdominal carcinomatosis and intractable ascites. Ten patients…”
Get more information

The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck by Suntharalingam, M, Haas, M L, Conley, B A, Egorin, M J, Levy, S, Sivasailam, S, Herman, J M, Jacobs, M C, Gray, W C, Ord, R A, Aisner, J A, Van Echo, D A

“…Unresectable squamous cell carcinomas of the head and neck (SCCHN) continue to pose a significant therapeutic challenge. This report defines the toxicities,…”
Get more information

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study by Parkinson, D R, Abrams, J S, Wiernik, P H, Rayner, A A, Margolin, K A, Van Echo, D A, Sznol, M, Dutcher, J P, Aronson, F R, Doroshow, J H

“…Forty-seven patients with metastatic malignant melanoma were treated with two 5-day cycles of 100,000 U/kg recombinant interleukin-2 (IL-2) intravenously (IV)…”
Get more information

Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck by Eisenberger, M, Hornedo, J, Silva, H, Donehower, R, Spaulding, M, Van Echo, D

“…Carboplatin (CBDCA, Bristol-Meyers, New York) is a second generation platinum analog. Preclinical and phase I clinical studies have indicated a different…”
Get more information

Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study by Lichtman, S M, Ratain, M J, Van Echo, D A, Rosner, G, Egorin, M J, Budman, D R, Vogelzang, N J, Norton, L, Schilsky, R L

“…Chemotherapy-induced myelosuppression often limits escalation of cancer chemotherapy doses. Cyclophosphamide, an alkylating agent, is an ideal candidate for…”
Get more information

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study by Ratain, M J, Rosner, G, Allen, S L, Costanza, M, Van Echo, D A, Henderson, I C, Schilsky, R L

“…To determine if variability in toxicity of amonafide during phase II trials could be correlated with pharmacokinetic variability. Seventy-three patients…”
Get more information

A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer by Eisenberger, M, Krasnow, S, Ellenberg, S, Silva, H, Abrams, J, Sinibaldi, V, Van Echo, D, Aisner, J

“…Patients with recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) were stratified by performance status, extent of disease, and prior…”
Get more information

Hypersensitivity reactions from taxol by Weiss, R B, Donehower, R C, Wiernik, P H, Ohnuma, T, Gralla, R J, Trump, D L, Baker, Jr, J R, Van Echo, D A, Von Hoff, D D, Leyland-Jones, B

“…Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions…”
Get more information

A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide by Belani, C P, Egorin, M J, Abrams, J S, Hiponia, D, Eisenberger, M, Aisner, J, Van Echo, D A

“…Thrombocytopenia, the dose-limiting toxicity of carboplatin, is manageable and predictable with the dosing equation: Dose (mg/m2) = (0.091) (creatinine…”
Get more information

Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia by Lee, E J, Egorin, M J, Van Echo, D A, Cohen, A E, Tait, N, Schiffer, C A

“…Sixteen patients [13 acute nonlymphocytic leukemia (ANLL), 2 acute lymphocytic leukemia, 1 chronic myelogenous leukemia in a blast crisis; median age, 40 yr;…”
Get more information

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics by CONLEY, B. A, EGORIN, M. J, SRIDHARA, R, FINLEY, R, HEMADY, R, WU, S, TAIT, N. S, VAN ECHO, D. A

“…A phase I trial of all-trans-retinoic acid (ATRA) was conducted to establish the maximum tolerable dose (MTD) of ATRA given once daily to patients with solid…”
Get full text

High-dose chemotherapy without autologous bone marrow transplantation in melanoma by Tchekmedyian, N S, Tait, N, Van Echo, D, Aisner, J

“…High-dose chemotherapy with BCNU, melphalan, or both, followed by autologous bone marrow transplantation (ABMT) has been reported to produce response rates in…”
Get more information

592 POSTER Obatoclax (GX17–070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC) by Chiappori, A, Williams, C, Northfelt, D, Adams, J, Malik, S, Edelman, M, Rosen, P, Van Echo, D, Berger, M, Haura, E

Get full text

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck by Suntharalingam, Mohan, Haas, Michael L., Van Echo, David A., Haddad, Robert, Jacobs, Maria C., Levy, Sharon, Gray, William C., Ord, Robert A., Conley, Barbara A.

“…BACKGROUND The objective of this study was to determine prognostic factors for response and survival on three consecutive institutional trials utilizing…”
Get full text

Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function by EGORIN, M. J, VAN ECHO, D. A, TIPPING, S. J, OLMAN, E. A, WHITACRE, M. Y, THOMPSON, B. W, AISNER, J

“…cis-Diammine(1,1-cyclobutanedicarboxylato)platinum (CBDCA) is a nonnephrotoxic but myelosuppressive analogue of cisplatin (DDP) with greatly reduced protein…”
Get full text

Mitomycin C and vinblastine chemotherapy for advanced breast cancer by Konits, P H, Aisner, J, van Echo, D A, Lichtenfeld, K, Wiernik, P H

“…Mitomycin C, 20 mg/m2 day 1, and vinblastine, 0.15 mg/m2 days 1 and 21, were administered intravenously to 31 patients with refractory previously treated…”
Get more information

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum by EGORIN, M. J, VAN ECHO, D. A, OLMAN, E. A, WHITACRE, M. Y, FORREST, A, AISNER, J

“…We previously correlated both renal function and thrombocytopenia, the dose limiting toxicity of carboplatin, with the plasma pharmacokinetics of carboplatin…”
Get full text

Diaziquone Given as a Continuous Infusion Is an Active Agent for Relapsed Adult Acute Nonlymphocytic Leukemia by Lee, Edward J., Van Echo, David A., Egorin, Merrill J., Nayar, M.S. Balchandran, Shulman, Philip, Schiffer, Charles A.

“…Diaziquone given as a bolus has not been effective in patients with relapsed or refractory leukemia. Because of in vitro data suggesting enhancement of…”
Get full text